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The effect of inhaled glucocorticosteroids in 
emphysema due to a,-antitrypsin deficiency 
J. T. R. WILCKE AND A. DIRKSEN 
Department of Pulmonary Medicine P, Bispebjerg Hospital, DK-2400 Copenhagen NV, Denmark 
Despite the success of inhaled steroids in controlling asthma, the benefit in patients with chronic 
obstructive pulmonary disease (COPD) remains controversial. Five subjects with moderate to severe 
emphysema due to a,-antitrypsin deficiency (phenotype PiZ) were followed with daily home spirometry 
in a 2 x 8 weeks, randomized double-blind, placebo-controlled, crossover study of inhaled budesonide 
0.8 mg b.i.d. 
In three of the five patients, there was a statistically significant increase in the mean forced expiratory 
volume in 1 s (FEV,), and in two of these patients, there was also a statistically significant increase in the 
mean forced vital capacity (FVC) during budesonide treatment. A significant diurnal variation in FEV, 
and FVC was found in three and two patients, respectively, but did not change significantly during 
treatment. These findings emphasize the need for renewed evaluation of inhaled steroids in the treatment 
of patients with emphysema, and indicate that individual patients may have significant clinical 
improvement. 
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Introduction 
The place of glucocorticoid treatment in chronic 
obstructive pulmonary disease (COPD) is a 
matter of much debate. Three ongoing European 
studies [Euroscop, Isolde and the Copenhagen 
City Lung Study (l)] aim to assess whether 
inhaled steroids can reduce the decline in lung 
function in smoking COPD patients (2,3). Since 
the definition of bronchial asthma as reversible 
airways obstruction (4), flow limitation in 
COPD has been conceived as mainly irreversible. 
However, the introduction of small hand-held 
spirometers has made it possible to monitor lung 
function more closely by patient-administered 
serial spirometry (PASS). When applying PASS 
to patients with severe a, -antitrypsin deficiency 
and emphysema, the authors were surprised to 
find a diurnal variation in the forced expiratory 
volume in 1 s (FEV,) and the forced vital 
Received 10 May 1996 and accepted 18 May 1996. 
Correspondence should be addressed to: J. T. R. Wilcke, 
Department of Pulmonary Medicine P, Bispebjerg 
Hospital, Bispebjerg Bakke 23, 2400 Copenhagen NV, 
Denmark. 
0954.6111/97/050275+05 $12.00/O 
capacity (FVC) similar to asthmatics. This 
observation led the authors to reconsider the 
short-term effect of inhaled steroids on the 
airways obstruction in these patients in a 
randomized, controlled, crossover study. 
Materials and Methods 
SUBJECTS 
Five patients (two men and three women) par- 
ticipated in the present study, aged 46-58 years 
(mean 53 years), with severe a,-antitrypsin 
deficiency [phenotype PiZ verified by isoelectric 
focusing (5)] and moderate to severe emphysema 
(0.901<FEV,<1.33 l-28% pred.<FEV,<52% 
pred. (6); 2.5 mmol kPa - ’ min - ’ <single breath 
CO diffusing capacity (0,,)<6*9 mmol kPa- ’ 
min - ’ N 34% pred.<D,.<68% pred. (6); 
5.43 l<total lung capacity (TLC) (body 
box)<9.57 l- 120% pred.<TLC<154% pred. 
(6)]. Baseline FEV, and FVC and diurnal vari- 
ations in FEV’ and FVC are shown in Table 1. 
Although all subjects were treated with 
inhaled steroids at inclusion, none had a history 
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of bronchial asthma, that is they denied dysp- 
noea at night and attacks of wheezing, and a 
skin prick test with 10 common aero-allergens 
was negative. All participants were former 
smokers (> 10 pack-years), and they had ab- 
stained from smoking for at least the previous 
year (checked several times by urine cotinine). 
All patients had been clinically stable, with un- 
changed medication for at least 3 months prior 
to inclusion, and none received treatment with 
oral steroids, P-blockers or cromolyn sodium. 
Each subject provided informed written and oral 
consent, and the study was approved by the local 
Medical Ethics Committee of Copenhagen and 
by the Danish Drug Administration. 
PATIENT-ADMINISTERED SERIAL SPIROMETRY 
(PASS) 
Pocket-sized turbine spirometers (MicroMedical 
DiaryCard, MicroMedical Ltd., Rochester, 
U.K.), attached by a cable to a small control 
unit with keypad, graphical/a-numeric display, 
microprocessor and clock/calender, were used. 
The control unit has memory for several 
hundred spirometric recordings including 
graphical storage of flow-volume curves. The 
calibration of the spirometers was checked at 
4-week intervals (7). 
The participants were instructed in spirometry 
for about 1 h, and they received written informa- 
tion on how to perform spirometry at home. 
Spirometry was to be performed 30 min after 
inhalation of bronchodilator every morning and 
evening. A measuring sequence included at least 
three maximal forced expiratory manoeuvres 
from maximal inspiration, with each blow last- 
ing at least 10 s. The patients could follow the 
progress of their blow semiquantitatively by 
small squares coming up on the display of the 
spirometer, and after 10 s, the control unit gave 
a ‘bleep’. Apart from this, results of the spiro- 
metry were not shown on the display (i.e. 
patients were blinded). After a learning period of 
at least 1 month, all patients were able to pro- 
duce technically acceptable flow-volume loops. 
The results reported are the greatest FEV, and 
FVC values achieved from at least three techni- 
cally acceptable manoeuvres, irrespective of the 
manoeuvre in which they occur. For FEV, and 
FVC to be considered technically acceptable, the 
0.5 1 I I 1 I I J 
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FIG. 1. Daily spirometries of Patient 1, who had 
the largest diurnal variation, but no effect of 
inhaled budesonide. -, placebo; . ., active. 
test had to be performed correctly (inspection of 
curve and time to peak flow ~300 ms) and the 
chosen values should not exceed the next highest 
by more than 5% or O-1 1, whichever is the 
greater (8). 
DESIGN 
In a double-blind, crossover study with two 
8-week treatment periods, the subjects were ran- 
domized to start with either Turbuhaler placebo 
or Turbuhaler budesonide 0.8 mg b.i.d. To avoid 
possible carry-over effects, only data from the 
last 5 weeks of every &week treatment period 
were used for analysis. For each treatment 
period, mean FEV,, FVC and mean diurnal 
variation in FEV, and FVC were calculated. The 
influence of budesonide on these dependent vari- 
ables was analysed by linear regression. A two- 
tailed probability value (P) of less than 0.05 was 
considered statistically significant. 
Results 
Daily lung function measurements of Patient 1 
are shown in Fig. 1. During budesonide treat- 
ment, the mean value of FEVi improved in four 
of five patients, and in three patients, the 
responses were statistically significant (Table 1). 
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Two of these three patients also improved sig- 
nificantly in FVC. Peak expiratory flow (PEF) 
followed FEV,. Significant diurnal variation in 
FEV, was seen in three patients, and during 
active treatment, this variation improved in one 
patient only (Table 1). No side-effects were 
observed. 
Discussion 
The results indicate that patients with well- 
defined emphysema due to a,-antitrypsin 
deficiency may benefit from treatment with 
inhaled steroids. Furthermore, a diurnal vari- 
ation in lung function was observed, similar to 
the well-known variation in asthmatics, i.e. with 
low morning values and higher values in the 
evening. In accordance with a previous study of 
both asthma and COPD patients, no influence 
of steroid treatment on the magnitude of the 
diurnal variation was found (9). 
Two retrospective studies on non-allergic 
COPD patients have shown a favourable effect 
of prednisolone 2 10 mg day - ’ on symptoms, 
exacerbations and FEV, over 20 yr follow-up 
(10,ll). Previous controlled, short-term studies 
of glucocorticosteroids in COPD show variable 
results (12-16), and because the distinction 
between COPD and asthma may be impossible 
(17), any previously reported effect of steroids in 
COPD may simply be explained by some min- 
gling of asthmatics with the study populations. 
However, in the present study, the authors are 
confident that the subjects did not have asthma. 
Severe a,-antitrypsin deficiency is a genetic 
abnormality that leads to emphysema, but not to 
bronchial asthma (18). The diagnosis of emphy- 
sema was further confirmed in all subjects by a 
smoking history of more than 10 pack-years, an 
age above 45 years, a D,, below 70% predicted, 
and a TLC above 120% predicted. Obviously, 
bronchial asthma cannot be excluded with cer- 
tainty in any patient with airflow limitations; 
however, the present subjects denied symptoms 
typical of asthma, i.e. their symptoms were rela- 
tively stable without wheezy attacks or nocturnal 
dyspnoea, and they showed no signs of atopy, i.e 
skin tests were negative. Due to the low lung 
function in some of the subjects, their bronchial 
hyper-reactivity was not determined. The results 
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FIG. 2. Effect on daily spirometries in Patient 1 
after increasing the dose of p.r.n. inhaled &agonist 
10 times (changed from inhalation of dry powder 
terbutaline 0.5 mg dose - 1 to nebulized terbutaline 
5 mg dose - ‘). 
of this test had probably not contributed to 
the differential diagnosis in these patients with 
moderate to severe airways obstruction. 
Patient-administered serial spirometry is a 
new concept with great potential. The concept 
improves the statistical power of clinical trials by 
combining close monitoring with high-quality 
measurements (19). Although in the present 
study, the reversibility of FEV, was of less 
magnitude (C 10% of baseline), compared to 
what is usually seen in asthmatics, nevertheless 
the reversibility reached statistical significance in 
three of five subjects. Thus, the lung function of 
emphysematous patients seems more susceptible 
to the influence of treatment than is usually 
assumed. This is also demonstrated in Fig. 2, 
which shows the lung function of one of the 
subjects who, more than 1 yr before entering into 
the present study, improved FEV, by approxi- 
mately 20% by increasing 10 times the dosage of 
p.r.n. bronchodilator (from terbutaline 0.5 mg 
by turbuhaler to terbutaline 5 mg by nebulizer). 
The Lung Health Study showed that broncho- 
dilators do not change the decline in lung 
function in patients with COPD (20). 
The major mechanisms of airflow limitation in 
emphysema are usually stated as irreversible, 
such as a loss of elastic recoil in the alveolar 
structures supporting the peripheral airways, and 
a destruction of the alveolar attachments to the 
outer wall of the small airways. The present 
findings indicate that reversible factors, such as a 
chronic inflammatory process in the wall and the 
lumen of peripheral airways, may also play a role. 
Although the reversibility of FEV, was statis- 
tically significant in three of five patients in the 
present study, the overall mean change in FEV, 
was small, and in itself of questionable clinical 
importance. However, the big issue is whether 
some of this short-term effect is due to a reduc- 
tion in the relentless decline of FEV, in these 
subjects. If so, the impact of inhaled steroids on 
long-term lung function and survival of patients 
with progressive emphysema may prove import- 
ant. Three ongoing European studies of the 
long-term effect of inhaled steroids in COPD 
(l-3) may solve this issue. 
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